ABSTRACT NUMBER: ESOC2026OT111 REDUCING DIETARY SODIUM WITH SALICORNIA VEGETABLE SALT: A CLINICAL-EXPERIMENTAL STRATEGY TO PREVENT CEREBRAL SMALL VESSEL DISEASE AND COGNITIVE DECLINE Authors: Emilio Montero Ramírez, Soledad Pérez Sánchez, Carmen del Rio Mercado, Cristina López Ázcarate, Alexandra Carolina Sevilla, Ana Dominguez Mayoral, Reyes De Torres-Chacon, Enma Narváez Gómez, Alejandro González, Joan Montaner Published: 2026 ABSTRACT AbstractBackground and aimsExcess dietary sodium intake is a major contributor to hypertension and vascular disease and has recently been implicated in cerebral small vessel disease and vascular cognitive impairment through mechanisms beyond blood pressure, including endothelial dysfunction and tau pathology. Despite clear recommendations, sodium consumption remains excessively high due to poor long-term adherence. Substitution of regular salt with plant-based alternatives derived from Salicornia, naturally lower in sodium and enriched in potassium, fiber, and polyphenols, may offer a feasible and sustainable strategy to improve cerebrovascular health and delay cognitive decline.MethodsTo determine whether reducing dietary sodium by substituting Salicornia-derived vegetable salt (50% less sodium) improves neurovascular function and cognitive outcomes. Secondary aims include identifying vascular and molecular biomarkers and estimating potential population-level effects.ResultsThe project combines preclinical and clinical approaches. In spontaneously hypertensive rats, vegetable salt will be compared with regular salt, assessing cognition, vascular stiffness, neuroimaging, histopathology, and proteomic biomarkers. A prospective, randomized, open-label pilot trial in individuals ≥60 years with transient ischemic attack, small vessel cerebrovascular disease, or cognitive impairment will compare Salicornia salt versus conventional salt over six months. Outcomes include 24-hour urinary sodium, blood pressure, pulse wave velocity, and cognitive performance (MoCA). The project also includes discovery of proteomic biomarkers and population-level analyses using electronic health records to investigate hypertension, treatments, stroke, and cognitive outcomes.ConclusionsPrimary outcomes include cognitive performance and vascular aging markers. Secondary outcomes include blood pressure control, sodium reduction, molecular signatures, and sex-specific effects.Conflict of interest